JPWO2020023923A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020023923A5 JPWO2020023923A5 JP2021503108A JP2021503108A JPWO2020023923A5 JP WO2020023923 A5 JPWO2020023923 A5 JP WO2020023923A5 JP 2021503108 A JP2021503108 A JP 2021503108A JP 2021503108 A JP2021503108 A JP 2021503108A JP WO2020023923 A5 JPWO2020023923 A5 JP WO2020023923A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- acceptable salt
- fenfluramine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 claims description 9
- MLBHFBKZUPLWBD-SSDOTTSWSA-N (2R)-1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound C[C@@H](N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-SSDOTTSWSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 5
- CJAVTWRYCDNHSM-CQSZACIVSA-N 2-[[(2r)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amino]ethyl benzoate Chemical compound C([C@@H](C)NCCOC(=O)C=1C=CC=CC=1)C1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-CQSZACIVSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 9
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 208000037012 Psychomotor seizures Diseases 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| US62/711,051 | 2018-07-27 | ||
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021530541A JP2021530541A (ja) | 2021-11-11 |
| JPWO2020023923A5 true JPWO2020023923A5 (enExample) | 2022-08-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503108A Pending JP2021530541A (ja) | 2018-07-27 | 2019-07-26 | てんかんの治療方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| HUE053114T2 (hu) | 2015-12-22 | 2021-06-28 | Zogenix International Ltd | Fenfluramin kompozíciók és eljárások azok elõállítására |
| WO2018037306A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| SG11202104378SA (en) | 2018-11-19 | 2021-05-28 | Zogenix International Ltd | Methods of treating rett syndrome using fenfluramine |
| EP3999570A1 (en) * | 2019-07-18 | 2022-05-25 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4395753A4 (en) * | 2021-09-01 | 2025-05-07 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ATE199829T1 (de) | 1994-06-03 | 2001-04-15 | Thejmde Trust | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon |
| US6416780B1 (en) | 1997-05-07 | 2002-07-09 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EP3636264A1 (en) * | 2013-08-19 | 2020-04-15 | The Regents of the University of California | Compounds and methods for treating an epileptic disorder |
| HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277272B1 (en) | Rimegepant for cgrp related disorders | |
| JP2019059760A5 (enExample) | ||
| US20050245460A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| JP2018520189A5 (enExample) | ||
| US10987324B2 (en) | Methods and compositions for the treatment of seizure-related disorders | |
| US20090253728A1 (en) | Methods and Compositions for Treating Nociceptive Pain | |
| JP2002532392A5 (enExample) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| US20080118556A1 (en) | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone | |
| JPWO2020023923A5 (enExample) | ||
| JP2019131588A5 (ja) | 抗そう痒剤 | |
| JP2022153638A5 (enExample) | ||
| JP2002524415A5 (enExample) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| US20160228388A1 (en) | Methods of administering amantadine compositions | |
| ES2216296T3 (es) | Formulacion farmaceutica que libera de manera controlada, con un agente inhibidor de la ace como sustancia activa. | |
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| HUE030963T2 (en) | Sustained release formulations containing a 2-oxo-pyrrolidine derivative | |
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| JPWO2023078333A5 (enExample) | ||
| JPWO2021023811A5 (enExample) | ||
| JP2019514935A5 (enExample) | ||
| US20090297597A1 (en) | Modified Release Ticlopidine Compositions | |
| EP1901718A1 (en) | Modified release ticlopidine compositions |